Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $15.3 million, representing a 36% increase compared to Q4 2023 [6][17] - U.S. Heart Failure revenue grew by 41% to $14.3 million, driven by an increase in active implanting centers and revenue units [17][18] - Gross profit for Q4 was $12.8 million, with a gross margin of 83%, down from 85% in the previous year [20] - Net loss for Q4 was $10.7 million, or $0.43 per share, compared to a net loss of $9.2 million, or $0.44 per share in Q4 2023 [23] Business Line Data and Key Metrics Changes - U.S. Heart Failure business showed significant growth, with 457 revenue units sold in Q4 2024 compared to 330 in Q4 2023 [17][18] - European revenue remained flat at $1 million, with a decrease in revenue units from 52 to 41 [19] Market Data and Key Metrics Changes - The company expanded to 48 sales territories in the U.S. by the end of 2024, up from 38 at the end of 2023 [18] - Active implanting centers increased to 223 from 178 at the end of 2023 [18] Company Strategy and Development Direction - The company is focused on building a world-class sales organization and developing sustainable Barostim programs [27][28] - Targeting centers with high heart failure patient volumes and proven adoption of new therapies is a key strategy [29] - The company aims to address barriers to adoption through increased awareness, clinical evidence, and patient access initiatives [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2025, supported by a clear reimbursement landscape and increasing awareness of Barostim therapy [26][15] - The company plans to maintain appropriate payment levels for procedures and leverage long-term data to influence coverage policies [33] Other Important Information - The company expects total revenue for 2025 to be between $63 million and $65 million, with a gross margin of 83% to 84% [25] - Cash and cash equivalents as of December 31, 2024, were $105.9 million [24] Q&A Session Summary Question: Revenue guidance for next year and utilization strategies - Management indicated that revenue guidance includes assumptions about average selling prices and new active implanting centers, expecting high single to low double-digit net adds quarterly [37][38] Question: Operating expenses and spending priorities - Management noted that the increase in operating expenses is primarily directed towards sales and marketing, with expectations for cash burn to decrease year-over-year [41][42] Question: Sales rep compensation and retention strategies - Management highlighted a more inclusive process for developing compensation plans, which has been well received by the sales team [50][51] Question: Addressing barriers to adoption for heart failure specialists - Management discussed ongoing efforts to improve awareness, clinical evidence, and patient access to Barostim therapy [61][63] Question: Inpatient reimbursement impact and international territory reduction - Management confirmed no material shift in procedure locations post-reimbursement changes and noted a strategic decision to reduce spending in Europe [68][69] Question: Units per center performance and future growth - Management reported an increase in revenue units per active implanting center, attributing this to improved education and focus on the right centers [75] Question: Advocacy for reimbursement codes and RVUs - Management confirmed ongoing engagement with CMS regarding permanent procedural codes and expressed confidence in achieving favorable RVUs [99][103]

Core Viewpoint - CVRx, Inc. reported strong financial performance in Q4 2024, driven by growth in its U.S. Heart Failure business, with total revenue reaching $15.3 million, a 36% increase compared to Q4 2023, and U.S. Heart Failure revenue growing by 41% [5]. Financial Performance - Total revenue for Q4 2024 was $15.3 million, marking a 36% year-over-year growth [5]. - Revenue from the U.S. Heart Failure segment grew by 41% compared to the same quarter in the previous year [5].

Revenue Expectations - Total revenue for Q4 2024 is expected to be approximately $15.2 million to $15.3 million, a 35% increase from Q4 2023 revenue of $11.3 million[8] - Full year 2024 total revenue is expected to be in the range of $51.1 million to $51.2 million, representing a 30% increase over 2023 revenue of $39.3 million[10] - U.S. revenue for Q4 2024 is expected to be approximately $14.2 million to $14.3 million, while European revenue is expected to be $1.0 million[8] Operational Metrics - As of December 31, 2024, the company had 223 active implanting centers in the U.S., up from 208 as of September 30, 2024[11] - The number of sales territories in the U.S. increased by three to a total of 48 during Q4 2024[11] Financial Position - Cash and cash equivalents as of December 31, 2024, were $105.9 million[12] - The company issued 869,059 shares of common stock for gross proceeds of $12.8 million under its at-the-market offering during Q4 2024[9] Financial Reporting - The estimated financial results for Q4 and full year 2024 are preliminary and unaudited, with actual results expected to be released in early February 2025[13]

Core Insights - CVRx, Inc. reported strong financial results for Q4 and full year 2024, with a focus on expanding its Barostim therapy for heart failure patients [3][4][15] Financial Performance - Q4 2024 revenue reached $15.3 million, a 36% increase from Q4 2023 [4] - U.S. heart failure revenue for Q4 2024 was $14.3 million, reflecting a 41% growth year-over-year [5] - Total revenue for 2024 was $51.3 million, up 31% from 2023 [15] - Gross profit for Q4 2024 was $12.8 million, a 33% increase from the previous year, with a gross margin of 83% [8][19] - The company reported a net loss of $10.7 million for Q4 2024, compared to a net loss of $9.2 million in Q4 2023 [13] Operational Highlights - Active implanting centers increased to 223 as of December 31, 2024, a 25% rise from the previous year [10][17] - The number of sales territories in the U.S. grew to 48, up from 38 in 2023 [17] - R&D expenses for Q4 2024 increased by 25% to $2.8 million, driven by clinical study costs [9] - SG&A expenses rose by 19% to $20.2 million, primarily due to increased headcount and compensation [10] Market Outlook - For Q1 2025, the company anticipates total revenue between $14.5 million and $15.0 million [26] - The full-year 2025 revenue is projected to be between $63.0 million and $65.0 million, with a gross margin between 83% and 84% [31]

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30%Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited fourth quarter and full year 2024 revenue r ...

MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at ir.cvrx.com. About CVRx, I ...

MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, In ...

CVRx (NASDAQ: CVRX ) is an impressive medical device company that has a unique product with impressive top-line growth. Furthermore, recent reimbursement news and approval from medical authorities increases sales potential as insurers are willing to cover Barostim. While I am impressed byAmateur value investor seeking bargains in any market, with a specific focus on emerging markets. Admires great investors such as Li Lu and Peter Lynch, and am not afraid to go against the grain. Willing to buy any company ...